{
    "pmcid": "11140877",
    "qa_pairs": {
        "What are nanobodies derived from?": [
            "The variable domain of camelid or shark heavy-chain antibodies.",
            "The constant domain of human antibodies.",
            "The light chain of mouse antibodies.",
            "The Fc region of rabbit antibodies."
        ],
        "What is a key advantage of nanobodies over conventional antibodies?": [
            "They have low immunogenicity in humans.",
            "They have a larger size, allowing for more complex structures.",
            "They are derived from human antibodies, reducing the need for humanization.",
            "They are less stable under extreme conditions."
        ],
        "What is a primary target for nanobody development against SARS-CoV-2?": [
            "The spike (S) protein, particularly its receptor-binding domain (RBD).",
            "The nucleocapsid protein.",
            "The membrane protein.",
            "The envelope protein."
        ],
        "What is a promising target for developing universal nanobodies with broad-spectrum activity?": [
            "The S2 region of the spike protein.",
            "The N-terminal domain of the nucleocapsid protein.",
            "The transmembrane domain of the envelope protein.",
            "The cytoplasmic tail of the membrane protein."
        ],
        "Which delivery methods have been used for nanobodies in animal models?": [
            "Intraperitoneal, aerosol, and intranasal routes.",
            "Intravenous, subcutaneous, and oral routes.",
            "Topical, transdermal, and rectal routes.",
            "Intramuscular, sublingual, and buccal routes."
        ]
    }
}